Key insights
- The author presents a bullish case for Blue Owl Technology Finance (OTF), highlighting its high dividend yield, low leverage, and significant discount to NAV. They analyze the portfolio's exposure to AI, arguing that even with stress-testing on AI-impacted holdings, the NAV impact is manageable. A recent loan sale at near par value supports the argument that OTF is undervalued, suggesting a positive outlook for the stock and potentially the broader BDC sector.
The numbers at $11
NAV per share is $17.33. Base dividend is $1.40/year (12.5% yield), plus $0.05 quarterly specials through September 2026. Non-accruals at 0.2% of fair value vs 3.6% sector average. Leverage at 0.75x against a 0.90-1.25x target. $2.3B in liquidity. Net LTV of 34%, meaning 66 cents of PE equity sits below every dollar of OTF debt. P/E is 6.5x.
I bucketed every holding by actual AI risk.
~28% benefits from AI. Arctic Wolf ($271M, cybersecurity). Forescout ($154M, IoT security). Checkmarx ($148M, AppSec). Delinea ($105M, access management). Proofpoint ($137M, email security). Databricks ($115M, literally an AI/data platform). More AI = more threats = more security spend.
~56% has zero AI relevance. Healthcare IT is the biggest piece: Inovalon ($260M), Datavant ($199M), ModMed ($147M), Hyland ($148M), Intelerad ($163M). Financial services tech: Computer Services Inc ($229M, their biggest position, core banking for community banks), Inspira Financial ($187M, HSA/retirement), Billtrust ($151M, AR automation). Boring, regulated, deeply embedded. Also Catalent ($173M, pharma manufacturing), Circana ($187M, market research data), Associa ($137M, HOA management).
~16% has genuine AI pressure. Zendesk ($169M), Sitecore ($308M, biggest position, enterprise CMS), Anaplan ($124M, FP&A planning), New Relic ($212M, observability), Alteryx ($94M, data prep), Cornerstone OnDemand ($65M, second lien LMS). These are the real risks.
But 16% of the book at 34% LTV means the borrower's value has to get cut in half before the first-lien debt is impaired. PE equity absorbs losses first. Even stress-testing these names at 30-50% fair value declines, the portfolio-wide NAV hit is 7-10%. The stock is already down 48%.
Recent Loan Sale
February 2026. Blue Owl sold $1.4B of loans to four pension funds and an insurer at 99.7 cents on the dollar. Sophisticated institutional buyers did their own due diligence and paid basically par.
Liquidity fears are misplaced
OTF is a publicly traded stock on the NYSE. You sell whenever you want. 2M+ shares daily volume. No gates, no redemption queues. The OBDC II lockup was a different product (non-traded fund with structural problems). Completely separate.
The numbers around the dividend.
Q4 adjusted NII was $0.30 against a $0.35 regular dividend.
The reason: OTF is at 0.75x leverage vs a 0.90-1.25x target. They committed $2.3B in Q4 that hadn't started earning interest yet. As those loans fund and leverage ramps, NII goes up mechanically. Management guided $0.34 for Q1. By late 2026 at target leverage, estimates put NII at $0.37-0.40.
Specials expire after September 2026. After that, payout drops to $1.40/year which should be fully covered. And NAV has gone up four straight quarters ($17.09, $17.17, $17.27, $17.33) so the asset base isn't eroding.
I think this an insane buy opportunity.